Search form
Search
Login
Subscribe
Home
Country Intelligence
Industry Directory
Offsets / IC
Tenders
Australia
(13/week)
Haiti
(0/week)
Guyana
(0/week)
Honduras
(0/week)
Guatemala
(0/week)
View all
(13/week)
News
United States
(626/week)
Manufacturing
(450/week)
Energy
(343/week)
Technology
(477/week)
Other Manufacturing
(372/week)
Events
About us
Who we are
Our People
Partners
Contact us
LinkedIn
Login
Twitter
Register
Home
News
Rivaroxaban
Jun 14, 2018
XARELTO® (rivaroxaban) Associated with Significantly Reduced Time in Hospital and Decreased Costs Compared to Standard of Care in New Study of Patients with Low-Risk Pulmonary Embolism (PE)
May 24, 2018
AGC Biologics Cleared for Commercial Manufacture of Portola's FDA-Approved Andexxa®
May 24, 2018
New Real-World Study Finds Long-Term XARELTO® (rivaroxaban) Use Resulted in Fewer Strokes and Systemic Emboli Compared to Warfarin in Frail Patients with Non-Valvular Atrial Fibrillation
Feb 16, 2018
Global Stroke Prevention in Atrial Fibrillation Market 2017-2024: Survey of 213 Cardiologists in the US, Japan, and Five Major EU markets Sheds Light on Prescribing Trends in SPAF.
Jan 16, 2018
FDA Mini-Sentinel Assessment Confirms Safety and Effectiveness of XARELTO® (rivaroxaban) and its Association with a Lower Risk of Ischemic Stroke vs. Warfarin
Dec 11, 2017
Janssen Submits Supplemental New Drug Application to FDA Seeking New Indications for XARELTO® (rivaroxaban) for Patients with Chronic Coronary and/or Peripheral Artery Disease (CAD/PAD)
Nov 01, 2017
ASH 2017: Janssen to Present 40 Abstracts, Including 8 Oral Presentations, with New Data on DARZALEX® (daratumumab), IMBRUVICA® (ibrutinib) and Other Compounds from Robust Portfolio
Oct 30, 2017
FDA Approves New 10 mg Dosing for XARELTO® (rivaroxaban) to Reduce the Continued Risk of Venous Thromboembolism (VTE)
Oct 05, 2017
NAVIGATE ESUS Study Stopped Early Due to Comparable Efficacy in Treatment Arms
Aug 28, 2017
In Canadian-Led Phase III Clinical Study, Xarelto® when Combined with ASA Significantly Lowered the Combined Risk of Stroke, Cardiovascular Death, and Heart Attack in Patients with Chronic Coronary or Peripheral Artery Disease by 24%
Aug 27, 2017
XARELTO® (rivaroxaban) Significantly Reduced Major Cardiovascular Events in Patients with Stable Coronary and Peripheral Artery Disease in Pivotal Phase 3 Study
Aug 21, 2017
New XARELTO® (rivaroxaban) Data at ESC Congress 2017 Includes Late-Breaking Results from Landmark Phase 3 COMPASS Study
Jul 25, 2017
Report: More than 15,000 Adverse Events Linked to Xarelto in 2016
Jun 28, 2017
U.S. FDA Grants Priority Review of XARELTO® (rivaroxaban) sNDA for a 10 mg Dose to Reduce the Risk of Recurrent Venous Thromboembolism (VTE)
‹‹
Page 2
Latest News
May 7, 2024
CentralSquare Unveils CAD and 911 Call Handling in the Cloud at ENGAGE 2024
May 7, 2024
AV’s Switchblade 600 Selected for Tranche 1 of the U.S. Department of Defense’s Replicator Initiative
May 7, 2024
Parts Town Unlimited Advances to 43rd Position on Crain’s Chicago Business’ Largest Privately Held Companies...
May 7, 2024
SLB OneSubsea and Subsea7 Awarded Integrated Contract for OKEA’s North Sea Bestla Project
May 7, 2024
Powin Unveils Next-Generation Pod Platform at CLEANPOWER 2024
May 7, 2024
Godspeed Capital-Backed Special Aerospace Services (SAS) Acquires Quintron Systems
May 7, 2024
New Relic Launches Secure Developer Alliance to Scale Security Observability
May 7, 2024
Aurora Solar Welcomes Alex Honnold, Free Solo Rock Climber & Founder, Honnold Foundation to Advance Solar...
View all News
Agenda
29
October
United Kingdom
Copthorne Tara Hotel, London, UK
International Dismounted Soldier, 29-30 October 2024, Copthorne Tara Hotel, London, UK
Navigating the Evolving Battlespace: Enhancing the Capabilities of the Dismounted Soldier The modern battlefield...
24
September
United Kingdom
Hilton London Syon Park, London, UK
Defence Transformation Conference, 24-26 September 2024, Hilton London Syon Park, London, UK
Returning for its 8th year, Defence Transformation 2024 will feature an updated format that will address all aspects of...
17
June
France
Parc des Expositions de Paris Nord Villepinte ZAC Paris Nord 2, 93420 Villepinte – France (Halls 5a – 5b – 6)
Eurosatory 2024, 17 - 21 June 2024, Parc des Expositions de Paris Nord Villepinte ZAC Paris Nord 2, 93420 Villepinte – France (Halls 5a – 5b – 6)
Eurosatory 2024 There can be no sustainable world without peace and security. Founded in 1967, the exhibition...
View All Events